Ehemalige Forschungsgruppe Herrlich (bis 2022)

Publikationen

2022

  • CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
    Gerardo-Ramírez M, Keggenhoff FL, Giam V, Becker D, Groth M, Hartmann N, Straub BK, Morrison H, Galle PR, Marquardt JU, Herrlich P, Hartmann M
    Int J Mol Sci 2022, 23(15)

2021

  • The LIM domain protein nTRIP6 modulates the dynamics of myogenic differentiation.
    Norizadeh Abbariki T, Gonda Z, Kemler D, Urbanek P, Wagner T, Litfin M, Wang ZQ, Herrlich P, Kassel O
    Sci Rep 2021, 11(1), 12904
  • TRIP6 functions in brain ciliogenesis.
    Shukla S, Haenold* R, Urbánek* P, Frappart L, Monajembashi S, Grigaravicius P, Nagel S, Min WK, Tapias A, Kassel O, Heuer H, Wang ZQ, Ploubidou** A, Herrlich** P
    Nat Commun 2021, 12(1), 5887 * equal contribution, ** co-senior authors
  • Transcriptional Regulation
    Tuckermann J, Herrlich P, Caratti G
    In: Encyclopedia of Molecular Pharmacology (edited by Stefan Offermanns and Walter Rosenthal) 2021, Springer International Publishin

2020

  • A Caenorhabditis elegans ortholog of human selenium-binding protein 1 is a pro-aging factor protecting against selenite toxicity.
    Köhnlein* K, Urban* N, Guerrero-Gómez D, Steinbrenner H, Urbánek P, Priebs J, Koch P, Kaether C, Miranda-Vizuete A, Klotz LO
    Redox Biol 2020, 28, 101323 * equal contribution
  • CD44 (Cluster of differentiation 44) promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.
    Ma* J, Klemm* J, Gerardo-Ramírez M, Frappart L, Castven D, Becker D, Zoch A, Parent R, Bartosch B, Minnich K, Giovannini M, Danckwardt S, Hartmann N, Morrison H, Herrlich** P, Marquardt** JU, Hartmann** M
    Int J Cancer 2020, 147(9), 2564-77 * equal contribution, ** co-senior authors

2019

  • CD44 deletion suppresses atypia in the precancerous mouse testis.
    Li* H, Shukla* S, Frappart L, Herrlich** P, Ploubidou** A
    Mol Carcinog 2019, 58(5), 621-6 * equal contribution, ** co-corresponding authors

2018

  • Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling.
    Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M
    Cancer Cell 2018, 33(6), 1061-1077.e6
  • Gamma secretase dependent release of the CD44 cytoplasmic tail upregulates IFI16 in cd44-/- tumor cells, MEFs and macrophages.
    Schultz* K, Grieger (Lindner)* C, Li Y, Urbánek P, Ruschel A, Minnich K, Bruder D, Gereke M, Sechi A, Herrlich P
    PLoS One 2018, 13(12), e0207358 * equal contribution

2017

  • ADAM Metalloprotease-Released Cancer Biomarkers.
    Herrlich P, Herrlich A
    Trends Cancer 2017, 3(7), 482-90

Beste Publikation

Die JBC-Publikation zu Ectodomain Cleavage wurde als eine der besten JBC-Publikationen des Jahres ausgezeichnet.